Tale Of Two Pathways: Follow-On Biologics Move Forth In EU, Stall In U.S.
Executive Summary
The European Medicines Agency's endorsement of Sandoz' human growth hormone Omnitrope could put further pressure on U.S. regulators to develop an approval pathway for follow-on biologics